A randomized, open-labelled, parallel, comparative study of the efficacy and tolerability of rosuvastatin in low-density lipoprotein-cholestrol reduction using different dosing regimens of 5 mg daily, 10 mg daily and 10 mg on alternate days in Hong Kong Chinese type 2 diabetic patients.
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Dyslipidaemias; Lipid metabolism disorders
- Focus Therapeutic Use
- 18 Sep 2012 Status changed from recruiting to completed as reported by ISRCTN record.
- 31 Dec 2009 Astra Zeneca added as trial sponsor.
- 31 Dec 2009 New source identified and integrated (Chinese Clinical Trial Register record no. ChiCTR-TRC00000677).